These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38605414)

  • 1. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
    Salembier R; De Haes C; Bellemans J; Demeyere K; Van Den Broeck W; Sanders NN; Van Laere S; Lyons TR; Meyer E; Steenbrugge J
    Breast Cancer Res; 2024 Apr; 26(1):63. PubMed ID: 38605414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
    Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
    J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
    BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer.
    Steenbrugge J; Vander Elst N; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Dirix L; Van Laere S; Meyer E
    Front Immunol; 2019; 10():2928. PubMed ID: 31921184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model.
    Libreros S; Garcia-Areas R; Shibata Y; Carrio R; Torroella-Kouri M; Iragavarapu-Charyulu V
    Int J Cancer; 2012 Jul; 131(2):377-86. PubMed ID: 21866546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer.
    Taifour T; Attalla SS; Zuo D; Gu Y; Sanguin-Gendreau V; Proud H; Solymoss E; Bui T; Kuasne H; Papavasiliou V; Lee CG; Kamle S; Siegel PM; Elias JA; Park M; Muller WJ
    Immunity; 2023 Dec; 56(12):2755-2772.e8. PubMed ID: 38039967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel insights into paclitaxel's role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment.
    Choi Y; Kim SA; Jung H; Kim E; Kim YK; Kim S; Kim J; Lee Y; Jo MK; Woo J; Cho Y; Lee D; Choi H; Jeong C; Nam GH; Kwon M; Kim IS
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39009452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locally Trapping the C-C Chemokine Receptor Type 7 by Gene Delivery Nanoparticle Inhibits Lymphatic Metastasis Prior to Tumor Resection.
    An S; Tiruthani K; Wang Y; Xu L; Hu M; Li J; Song W; Jiang H; Sun J; Liu R; Huang L
    Small; 2019 Mar; 15(9):e1805182. PubMed ID: 30690891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer stem cell-derived CHI3L1 activates the MAF/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer.
    Ji S; Yu H; Zhou D; Fan X; Duan Y; Tan Y; Lang M; Shao G
    J Transl Med; 2023 Oct; 21(1):721. PubMed ID: 37838657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.
    O'Melia MJ; Manspeaker MP; Thomas SN
    Cancer Immunol Immunother; 2021 Aug; 70(8):2179-2195. PubMed ID: 33459842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
    Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer.
    Haq ATA; Yang PP; Jin C; Shih JH; Chen LM; Tseng HY; Chen YA; Weng YS; Wang LH; Snyder MP; Hsu HL
    Theranostics; 2024; 14(5):2167-2189. PubMed ID: 38505617
    [No Abstract]   [Full Text] [Related]  

  • 17. One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer.
    Steenbrugge J; Bellemans J; Vander Elst N; Demeyere K; De Vliegher J; Perera T; De Wever O; Van Den Broeck W; De Spiegelaere W; Sanders NN; Meyer E
    Oncoimmunology; 2022; 11(1):2103277. PubMed ID: 35898705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.
    Ma B; Akosman B; Kamle S; Lee CM; He CH; Koo JS; Lee CG; Elias JA
    J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34720089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SI-CLP inhibits the growth of mouse mammary adenocarcinoma by preventing recruitment of tumor-associated macrophages.
    Yin S; Wang N; Riabov V; Mossel DM; Larionova I; Schledzewski K; Trofimova O; Sevastyanova T; Zajakina A; Schmuttermaier C; Gratchev A; Flatley A; Kremmer E; Zavyalova M; Cherdyntseva N; Simon-Keller K; Marx A; Klüter H; Goerdt S; Kzhyshkowska J
    Int J Cancer; 2020 Mar; 146(5):1396-1408. PubMed ID: 31525266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.